169
Participants
Start Date
March 10, 2025
Primary Completion Date
April 30, 2025
Study Completion Date
July 1, 2025
TQH2722 injection
TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
TQH2722 Placebo
Placebo without drug substance.
Hebei Medical University Third Hospital, Shijiazhuang
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Peking University Third Hospital, Beijing
Shengjing Hospital of China Medical University, Shenyang
Liaoning Health Industry Group Iron Coal General Hospital, Tieling
Ansteel Group General hospital, Anshan
Shandong Second Provincial General Hospital, Jinan
Qilu Hospital of Shandong University, Qilu
Zibo Central Hospital, Zibo
Yantai Yuhuangding Hospital, Yantai
Tianjin Medical University General Hospital, Tianjin
Tianjin People's Hospital, Tianjin
Tianjin First Central Hospital, Tianjin
The Central Hospital of Wuhan, Wuhan
Union Hospital, Tongji Medical College, Huazhong University of science and technology, Wuhan
Tongji Hospital of Tongji medical college of HUST, Wuhan
Zhongnan Hospital of Wuhan University, Wuhan
Henan Provincial People's Hospital, Zhengzhou
The First Affiliated Hospital of Kunming Medical University, Kunming
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Gansu Provincial Hospital, Lanzhou
The First People's Hospital of Yinchuan, Yinchuan
The First Affiliated Hospital of Xinjiang Medical University, Ürümqi
Cangzhou Central Hospital, Cangzhou
Baotou Central Hospital, Baotou
Chifeng Municipal Hospital, Chifeng
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot
Shanxi Bethune Hospital, Taiyuan
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
INDUSTRY